Literature DB >> 22700876

PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.

Vincent W Keng1, Eric P Rahrmann, Adrienne L Watson, Barbara R Tschida, Christopher L Moertel, Walter J Jessen, Tilat A Rizvi, Margaret H Collins, Nancy Ratner, David A Largaespada.   

Abstract

The genetic evolution from a benign neurofibroma to a malignant sarcoma in patients with neurofibromatosis type 1 (NF1) syndrome remains unclear. Schwann cells and/or their precursor cells are believed to be the primary pathogenic cell in neurofibromas because they harbor biallelic neurofibromin 1 (NF1) gene mutations. However, the phosphatase and tensin homolog (Pten) and neurofibromatosis 1 (Nf1) genes recently were found to be comutated in high-grade peripheral nerve sheath tumors (PNST) in mice. In this study, we created transgenic mice that lack both Pten and Nf1 in Schwann cells and Schwann cell precursor cells to validate the role of these two genes in PNST formation in vivo. Haploinsufficiency or complete loss of Pten dramatically accelerated neurofibroma development and led to the development of higher grade PNSTs in the context of Nf1 loss. Pten dosage, together with Nf1 loss, was sufficient for the progression from low-grade to high-grade PNSTs. Genetic analysis of human malignant PNSTs (MPNST) also revealed downregulation of PTEN expression, suggesting that Pten-regulated pathways are major tumor-suppressive barriers to neurofibroma progression. Together, our findings establish a novel mouse model that can rapidly recapitulate the onset of human neurofibroma tumorigenesis and the progression to MPNSTs. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22700876      PMCID: PMC3428071          DOI: 10.1158/0008-5472.CAN-11-4092

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Confirmation of a double-hit model for the NF1 gene in benign neurofibromas.

Authors:  E Serra; S Puig; D Otero; A Gaona; H Kruyer; E Ars; X Estivill; C Lázaro
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

2.  Comprehensive NF1 screening on cultured Schwann cells from neurofibromas.

Authors:  Ophélia Maertens; Hilde Brems; Jo Vandesompele; Thomas De Raedt; Ine Heyns; Thorsten Rosenbaum; Sofie De Schepper; Anne De Paepe; Geert Mortier; Sandra Janssens; Frank Speleman; Eric Legius; Ludwine Messiaen
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

3.  Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation.

Authors:  Andrew Xiao; Chaoying Yin; Chunyu Yang; Antonio Di Cristofano; Pier Paolo Pandolfi; Terry Van Dyke
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

4.  Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.

Authors:  Biplab Dasgupta; Yijun Yi; David Y Chen; Jason D Weber; David H Gutmann
Journal:  Cancer Res       Date:  2005-04-01       Impact factor: 12.701

5.  A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma.

Authors:  Vincent W Keng; Augusto Villanueva; Derek Y Chiang; Adam J Dupuy; Barbara J Ryan; Ilze Matise; Kevin A T Silverstein; Aaron Sarver; Timothy K Starr; Keiko Akagi; Lino Tessarollo; Lara S Collier; Scott Powers; Scott W Lowe; Nancy A Jenkins; Neal G Copeland; Josep M Llovet; David A Largaespada
Journal:  Nat Biotechnol       Date:  2009-02-22       Impact factor: 54.908

6.  Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.

Authors:  Shyra J Miller; Fatima Rangwala; Jon Williams; Peter Ackerman; Sue Kong; Anil G Jegga; Sergio Kaiser; Bruce J Aronow; Silke Frahm; Lan Kluwe; Victor Mautner; Meena Upadhyaya; David Muir; Margaret Wallace; Jussara Hagen; Dawn E Quelle; Mark A Watson; Arie Perry; David H Gutmann; Nancy Ratner
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

7.  Comparative pathology of nerve sheath tumors in mouse models and humans.

Authors:  Anat O Stemmer-Rachamimov; David N Louis; Gunnlaugur P Nielsen; Cristina R Antonescu; Alexander D Borowsky; Roderick T Bronson; Dennis K Burns; Pascale Cervera; Margaret E McLaughlin; Guido Reifenberger; Michael C Schmale; Mia MacCollin; Richard C Chao; Karen Cichowski; Michel Kalamarides; Shanta M Messerli; Andrea I McClatchey; Michiko Niwa-Kawakita; Nancy Ratner; Karlyne M Reilly; Yuan Zhu; Marco Giovannini
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

8.  Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells.

Authors:  Jianqiang Wu; Jon P Williams; Tilat A Rizvi; Jennifer J Kordich; David Witte; Dies Meijer; Anat O Stemmer-Rachamimov; Jose A Cancelas; Nancy Ratner
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

9.  A transposon-based genetic screen in mice identifies genes altered in colorectal cancer.

Authors:  Timothy K Starr; Raha Allaei; Kevin A T Silverstein; Rodney A Staggs; Aaron L Sarver; Tracy L Bergemann; Mihir Gupta; M Gerard O'Sullivan; Ilze Matise; Adam J Dupuy; Lara S Collier; Scott Powers; Ann L Oberg; Yan W Asmann; Stephen N Thibodeau; Lino Tessarollo; Neal G Copeland; Nancy A Jenkins; Robert T Cormier; David A Largaespada
Journal:  Science       Date:  2009-02-26       Impact factor: 47.728

Review 10.  How does the Schwann cell lineage form tumors in NF1?

Authors:  Steven L Carroll; Nancy Ratner
Journal:  Glia       Date:  2008-11-01       Impact factor: 8.073

View more
  35 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

2.  Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors.

Authors:  Marjorie Carlson; Adrienne L Watson; Leah Anderson; David A Largaespada; Paolo P Provenzano
Journal:  J Biomed Opt       Date:  2017-11       Impact factor: 3.170

Review 3.  The NF1 gene in tumor syndromes and melanoma.

Authors:  Maija Kiuru; Klaus J Busam
Journal:  Lab Invest       Date:  2017-01-09       Impact factor: 5.662

Review 4.  The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Authors:  Souvik Karmakar; Karlyne M Reilly
Journal:  CNS Oncol       Date:  2016-12-21

Review 5.  Neurofibromatosis-related tumors: emerging biology and therapies.

Authors:  Matthias A Karajannis; Rosalie E Ferner
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

6.  Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.

Authors:  Adrienne L Watson; Eric P Rahrmann; Branden S Moriarity; Kwangmin Choi; Caitlin B Conboy; Andrew D Greeley; Amanda L Halfond; Leah K Anderson; Brian R Wahl; Vincent W Keng; Anthony E Rizzardi; Colleen L Forster; Margaret H Collins; Aaron L Sarver; Margaret R Wallace; Stephen C Schmechel; Nancy Ratner; David A Largaespada
Journal:  Cancer Discov       Date:  2013-03-27       Impact factor: 39.397

Review 7.  Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies.

Authors:  Barbara R Tschida; David A Largaespada; Vincent W Keng
Journal:  Semin Cell Dev Biol       Date:  2014-01-24       Impact factor: 7.727

8.  Adjuvant therapy for high-risk soft tissue sarcoma in the adult.

Authors:  Alessandro Gronchi; Paolo G Casali
Journal:  Curr Treat Options Oncol       Date:  2013-09

9.  The impact of coexisting genetic mutations on murine optic glioma biology.

Authors:  Aparna Kaul; Joseph A Toonen; Scott M Gianino; David H Gutmann
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

Review 10.  Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1.

Authors:  David H Gutmann
Journal:  Neurology       Date:  2014-06-27       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.